Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic cancer.
Huang ChenWenbo ZhouAiwu BianQiansen ZhangYing MiaoShifen XuJiangnan YeShi-Fen XuChaowen TiZhenliang SunJianghua ZhengYihua ChenMingyao LiuZheng-Fang YiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our work presents the First-in-class selective STAT3 inhibitor WB436B as a potential therapeutic candidate for the treatment of pancreatic cancer.